Manufacturing and Marketing permission issued from SND Division from to

Similar documents
Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from to

eltrombopag (Promacta )

04 September 2017 Page 1 of 6

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

Thrombopoietin Receptor Agonists Prior Authorization with Quantity Limit Program Summary

KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the

IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road 5)

Bosulif. Bosulif (bosutinib) Description

Rayos Prior Authorization Program Summary

Elements for a Public Summary

Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)

NB Drug Plans Formulary Update

What prescribers need to know

NICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017

Pharmacy Prior Authorization

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

Area Drug and Therapeutics Committee Prescribing Supplement No 59 July 2012

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?

Cigna Drug and Biologic Coverage Policy

Pharmacy Prior Authorization

Public Assessment Report Scientific discussion. Metoject Metojectpen (methotrexate disodium) SE/H/643/01/DC SE/H/643/02-11/DC

Product Visual Guide

For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation

Immune Modulating Drugs Prior Authorization Request Form

RITUXAN (rituximab and hyaluronidase human)

Appendix to Notification Letter for rituximab and eltrombopag dated 20 February 2014

IVIG (intravenous immunoglobulin) Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen

Peking University People's Hospital, Peking University Institute of Hematology

An Overview of Blood and Marrow Transplantation

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

Methotrexate Injectable Step Therapy Program Summary

Stem cell transplantation. Dr Mohammed Karodia NHLS & UP

Corporate Medical Policy

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

IMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical

Clinical Commissioning Policy Proposition: Rituximab for cytopaenia complicating primary immunodeficiency

Elements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Tasigna. Tasigna (nilotinib) Description

QUESTIONS OF HEMATOLOGY AND THEIR ANSWERS

Tasigna. Tasigna (nilotinib) Description

Medicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5

PEMBROLIZUMAB (KEYTRUDA ) for the treatment of advanced melanoma or previously treated NSCLC

Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation

VI.2 Elements for a public summary

Drugs approved from 1st January 2015 till present. S.NO Name Of Drug Indication Date of Approval 1 Levocetirizine ODS 2.5mg /5mg (Additional

Announcing HUMIRA. Psoriasis Starter Package

Summary of Strategic Competitive Analysis and Publication Planning

UNIVERSITY HOSPITAL OF HERAKLION DEPARTMENT OF HAEMATOLOGY

Rituxan (rituximab) DRUG POLICY BENEFIT APPLICATION

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

TRANSPARENCY COMMITTEE OPINION. 14 February 2007

Promacta (eltrombopag)

PROMACTA (eltrombopag olamine) oral tablet and oral suspension

Adjuvant therapy for thyroid cancer

HEALTH MATTERS, INC. SUMMARY OF PROJECTS AND KEY ACCOMPLISHMENTS TO 2016

Kevzara (sarilumab) NEW PRODUCT SLIDESHOW

HELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA

Promacta. Promacta (eltrombopag) Description

Actemra (tocilizumab) CG-DRUG-81

For practical information about using Revlimid, patients should read the package leaflet or contact their doctor or pharmacist.

NB Drug Plans Formulary Update

Stem Cell Transplantation for Severe Aplastic Anemia

Name of firm/applicant

Tavalisse (fostamatinib disodium hexahydrate)

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

CLINICAL MEDICATION POLICY

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440

PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) METHOTREXATE ORION 2.5 MG & 10 MG TABLET (METHOTREXATE DISODIUM) DATE: , VERSION 1.

Infliximab/Infliximab-dyyb DRUG.00002

Endocrine system pathology

Recommended Timing for Transplant Consultation

What s a Transplant? What s not?

New Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.

Opinion 23 July 2014

Overview of Aplastic Anemia. Overview of Aplastic Anemia. Epidemiology of aplastic anemia. Normal hematopoiesis 10/6/2017

QUICK REFERENCE Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)

8/11/2015. Febrile neutropenia Bone marrow transplant Immunosuppressant medications

Antifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary

Index. Note: Page numbers of article numbers are in boldface type.

How I treat acquired aplastic anemia

Thyroid Plus. Central Thyroid Regulation & Activity. Peripheral Thyroid Function. Thyroid Auto Immunity. Key Guide. Patient: DOB: Sex: F MRN:

Volume 10; Number 4 February 2016

Actimmune. Actimmune (interferon gamma-1b) Description

Treatment pathway for adult patients with immune (idiopathic) thrombocytopenic purpura (ITP)

STELARA (ustekinumab)

CLINICAL MEDICATION POLICY

Manipulation of the Immune Response - Immunomodulation -

BC Cancer Protocol Summary for Maintenance Therapy of Multiple Myeloma Using Lenalidomide

Chelsea and Westminster Hospital NHS Foundation Trust Trust Medicines Group

Promacta. Promacta (eltrombopag) Description

Summary of Main Points from the Meeting held on Monday 13 th February 2017

Remicade (infliximab) DRUG.00002

Transcription:

Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial contains: chemotherapeutic regiment for the 1 3750 Pegaspargase 3750 IU treatment of patients with acute 04-01-2018 IU per vial per vial lymphoblastic leukaemia who are hypersensitive to L-Asparaginase. 2 Cefditoren Pivoxil powder suspension 100mg/5ml Indication) dry for Each 5ml reconstituted suspension contains: Cefditoren Pivoxil equivalent to Cefditoren 100mg For the treatment of mild to moderate infection also in children s of (2 months to 12 years of age) which are caused by susceptible strains of the designated microorganisms in the condition listed below: Acute Bacterial Exacerbation of Chronic Bronchitis Community-Acquired pneumonia Pharyngitis/Tonsillitis Uncomplicated Skin and skin structure infection 04-01-2018 3 Eltrombopag olamine tablets 12.5mg strength & contains: Eltrombopag olamine equivalent to Eltrombopag olamine as free acid 12.5mg 1. Chronic ITP : for Adults For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) Thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. (It should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts). For Paediatric patients aged 1 year and above: Thrombocytopenia in paediatric patients 1 year and older with immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy (lt should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an 06-02-2018

attempt to normalize platelet counts). 4 5 6 7 Alectinib Capsules 150mg Fulvestrant 250mg/5ml Bendamustine hydrochloride 90mg/ml (0.5ml vial & 2.0 ml vial) Methotrexate prefilled 15mg/0.3ml, 20mg/0.4ml and 25mg/0.5ml strength & Each hard gelatin capsule contains: Alectinib 150mg equivalent to Alectinib hydrochloride 161.3mg Each 5ml pre-filled contains: Fulvestrant 250mg ethanol (96%)-10% w/v Each ml contains: Bendamustine hydrochloride 90mg ethanol 4.33% w/v Each 0.3ml prefilled ml contains: Methotrexate 15mg Each 0.4ml prefilled ml contains: Methotrexate 20mg Each 0.5ml prefilled ml contains: Methotrexate 25mg 2. For the treatment of patients with chronic Hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to: Enable the initiation of interferon based therapy, optimize interferon based therapy. on the prescription of Haematologist only First-line treatment of patients with Anaplastic Lymphoma Kinase (ALK) - positive locally advanced or metastatic non-small cell lung cancer (NSCLC). on For the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy on Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment. on the prescription of Oncologist/Specialist only. It is indicated in treatment of 1. Active rheumatoid arthritis in adult patients. 2. Polyarthritic forms of severe, active juvenile idiopathic arthritis, when the response to nonsteroidal antiinflammatory drug (NSAIDs) has been inadequate, 3. Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids and severe psoriatic arthritis in adult patients. 05-03-2018 20-03-2018 23-03-2018 09-03-2018 4. Mild to moderate Crohn's disease either

8 9 Sildenafil power for oral suspension 10mg/ml dosage form) Dydrogesterone tablet 10mg Each ml of reconstituted suspension contains: Sildenafil citrate equivalent to 10mg, Sodium benzoate 4.375mg contains: Dydrogesterone 10mg alone or in combination with corticosteroids in adult patients refractory or intolerant to thiopurines. Adults: Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Paediatric population: Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. on the prescription of Cardiologist only. Luteal support as part of an Assisted Reproductive Technology (ART) treatment. on the prescription of Gynaecologist only. 20-03-2018 06-04-2018 10 Febuxostat tablet 60mg & 20mg Strength) contains: Febuxostat 60mg & 20mg For the treatment of chronic hyperuricemia in conditions where urate deposition has already occurred (including a history, or presence of tophus and / or gouty arthritis) 06-04-2018 11 Posaconazole 300mg/16.7ml (18mg/ml) strength & dosage form) Each contains: Posaconazole 300mg/16.7ml For prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy. on the prescription of Specialist only. 13-04-2018 12 Teriflunomide tablet 7mg (Add. Lower contains: Teriflunomide 7mg For the treatment of patients with relapsing form of multiple sclerosis. on the prescription of Neurologist only. 07.05.2018

13 Apremilast film coated tablet 10/20/30mg Indication) contains: Apremilast- 10mg, 20mg,30mg For the treatment of adult patients with Active psoriatic Arthritis. 14 Aripiprazole tablet 2mg Each uncoated tablet contains: Aripiprazole- 2mg For the treatment of Schizophrenia in adolescent patients (13 to 17 years of age) on the prescription of Psychiatrist only. 15 Dextromethorp han HBr Lozenges 10mg (Add. dosage form & Each lozenges contains: Dextromethorphan HBr-33.33% Complex 30mg eq. to Dextromethorphan HBr 10mg Cough suppressant for the relief of acute non-productive (dry, tickly) cough associated with respiratory tract infection in adult patients only. 16 Voglibose Orally Disintegrating Strips 0.2mg (Modified dosage form) Each Orally Disintegrating Strips contains: Voglibose 0.2mg & 0.3mg For improvement of parandial hyperglycaemia in diabetes mellitus, when only diet and/or exercise or oral hypoglycaemic drugs or insulin preparation in addition to diet and/or exercise do not result in adequate glycemic control. 17 18 Tranexamic acid tablet 1000mg Eltrombopag Olamine Tablet 75mg contains: Tranexamic acid-1000mg. contains: Eltrombopag Olamine as free acid- 75mg For the treatment of menorrhagia 21.05.2018 1. For the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.(it should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts). 2. Indicated in patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to: a. Enable the intiation of interferon based therapy. 29.05.2018

b. Optimize interferon based therapy 3. For the treatment of patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy 4. For the treatment of thrombocytopenia in paediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. (It should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts). on the prescription of Hematologist only. 19 Thyroxine Sodium Tablet 37.5 mcg Each uncoated tablet contains: Thyroxine Sodium eq. to Anhydrous Thyroxine Sodium. 37.5 mcg. 1. As replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of sub-acute thyroiditis resultng from thyroid dysfunction, primary atrophy or partial or total absence of the thyroid gland or from the effects of surgery, radiation or drugs with or without the presence of goiter, including sub-clinical hypothyroidism; secondary (pituitary) hypothyroidism and tertiary (hypothalamic) hypothyroidism. 2. As a pituitary TSH suppressant in the treatment or prevention of various types of euthyroidgoites, including thyroid nodules, sub-acute or chronic lymphocytic thyroiditis (Hashimoto's) multi-nodular goiter and in conjuction with surgery and radioactive iodine therapy in the management of thyrotropin-dependent well differentiated papillary or follicular carcinoma of the thyroid. 08.06.2018

20 21 22 23 Dabrafenib Hard Gelatin Capsule 50mg,& 75mg Trametinib Tablet 0.5mg & 2mg Azacitidine for 50mg/vial Nilotinib Capsules 50mg strength & add. Each Hard Gelatin Capsule contains: Dabrafenib Mesylate eq. to Dabrafenib 50mg & 75mg Each Film coated tablet contains: Trametinib 0.5mg & 2mg Each vial contains: Azacitidine. 50mg Lyophilized power for (for subcutaneous or Intravenous use) Each Capsule contains: Nilotinib 50mg Dabrafenib in combination with Trametinib for the treatment of adult patients with advanced non-small cell lung cancer with BRAF V600 mutation. on Trametinib in combination with Dabrafenib for the treatment of adult patients with advance non-small cell lung cancer with a BRAF V 600 mutation. on For the treatment of adult patients with all subtypes of Myelodysplastic Syndrome. on 1. Paediatric patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia (CML) in the chronic phase. 2. Paediatric patients with chronic phase Philadelphia Chromosome Positive (CML) with resistance or intolerance to prior therapy including imatinib. on 08.06.2018 08.06.2018 22.06.2018 22.06.2018